Research Division

Zoonotic Virus Lab

We study emerging viruses, focusing on coronaviruses, mosquito-borne flaviviruses (e.g., dengue and Zika viruses), and tick-borne bunyavirus (e.g., SFTS virus). Our ultimate goal is to understand the biology of these viruses and to develop therapeutic interventions (e.g. small molecule inhibitors and therapeutic antibodies).
Viral Immunology Lab

We aim to understand immunological principles underlying response to viral infections and vaccinations in an effort to develop interventions for immune-associated diseases including infectious diseases and cancer.
Applied Molecular Virology Lab

Applied Molecular Virology Lab. is dedicated to conducting translational research developing therapeutics for viral disease. The main focus is viral hepatitis and Zika- and Ebola viruses are also being investigated. We study virus-host/human interactions to identify viral weaknesses.
Tuberculosis Lab

Tuberculosis (TB) remains a major public health challenge, largely affecting developing countries. The world needs new drugs and methodologies to reduce the duration of the therapy. We are committed to providing the means to facilitate the discovery and evaluation of new TB drugs.
Antibacterial Resistance Lab

Antibiotic resistance is a global public health threat estimated to risk a mortality rate of over 10 million people a year by 2050. We aim to discover new antibacterial agents and targets by understanding bacterial physiology and fundamental mechanisms of antibiotic resistance.
Host-Parasite Research Lab

To tackle neglected tropical diseases, such as leishmaniasis, we aim to discover next-generation therapeutics and develop rapid diagnostics. We study the biology of the host-cell/pathogen infection, notably the underlying mechanisms by which Leishmania hijacks macrophages for its survival and propagation.
Advanced Biomedical Research Lab

Our goal is to develop drugs to treat Hepatocellular carcinoma (HCC) and liver cirrhosis. We aim to think outside of the box by developing physiologically relevant assay systems recapitulating the tumor microenvironment and enhancing the early drug discovery pipeline converging to HCC therapeutics.